TELZIR (fosamprenavir calcium) is a protease inhibitor (PI) drug indicated for the treatment of human immunodeficiency virus (HIV-1) infection in combination with other antiretroviral drugs. Fosamprenavir is a prodrug that is quickly hydrolyzed to amprenavir. Amprenavir is an inhibitor of the enzyme, HIV-1 protease. Amprenavir binds to the active site of HIV-1 protease which prevents the processing of viral precursors. This results in the formation of immature non-infectious viral particles.
Dosing & Administration
TELZIR is indicated as part of a combination drug regimen for the treatment of HIV-1 infection and for the off-label use of post-exposure prophylaxis following HIV exposure in the occupational setting. It can be used in adults and pediatric patients age 6 months and up. TELZIR comes in tablet form and as an oral liquid solution. It can be taken with or without food. Dosages and prescribing considerations are detailed in the package insert.
TELZIR is contraindicated in patients taking certain medications (see list in package insert).
TELZIR is most commonly associated with diarrhea, rash, nausea, vomiting, and headache. A detailed list of potential adverse events is available in the package insert and should be reviewed by all prescribers.
TELZIR should be stopped for severe skin reactions including Stevens-Johnson syndrome. As well, this product should be used with caution in patients with a known sulfonamide allergy. TELZIR patients with hepatitis B or C are at increased risk of transaminase elevations. Also, patients on TELZIR may develop new onset or exacerbations of diabetes mellitus or hyperglycemia. Immune reconstitution syndrome may occur for patients on this product. An increase of body fat and elevated triglyceride and cholesterol concentrations have been shown. Acute hemolytic anemia has been reported with amprenavir. Hemophilia and nephrolithiasis cases have been reported with fosamprenavir.
TELZIR is associated with a number of drug-drug interactions and prescribers should familiarize themselves with the list provided in the package insert.
Pregnancy & Lactation
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to TELZIR during pregnancy. The purpose of the registry is to collect health information about the patient and the baby.
There is no information available on amprenavir presence in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production.
There is no known antidote for TELZIR overdose. It is unknown is TELZIR is dialyzable. Patients who overdose should be closely monitored and provided with supportive care.
Alternative Brand Names
TELZIR is known as Lexiva in the U.S.
Reviews are only written by verified customers who have purchased this product.